CCL2 and neoplasm: Moreover, PPARδ was found to dramatically accelerate pancreatic ductal adenocarcinoma development by activating the PPARδ-CCL2/CCR2 axis or the GOT2-PPARδ axis to drive immunosuppression through suppressing T cell-mediated anti-tumor immunity [40, 41].